|
rs10069690
|
|
|
0.020 |
GeneticVariation |
BEFREE |
In addition, we confirmed SNP rs10069690 was the best indicator for ER-negative breast cancer at 5p15.33 (OR = 1.30; P = 2.4 × 10 − 10) and identified rs12998806 as the best indicator for ER-positive breast cancer at 2q35 (OR = 1.34; P = 2.2 × 10 − 8) for women of African ancestry.
|
28171663 |
2016 |
|
rs700518
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Because AI use results in severe estrogen deficiency that may lead to changes in body composition, the aim of this study was to determine the effect of the rs700518 polymorphism in the CYP19A1 gene on the changes in body composition among postmenopausal women who were treated with AIs for ER+ breast cancer.
|
26049585 |
2015 |
|
rs2046210
|
|
|
0.020 |
GeneticVariation |
BEFREE |
When stratified by ER status, ESR1 rs1801132, rs2046210, and rs3020314 showed stronger associations in ER-positive than in ER-negative breast cancer in only EA women.
|
25228414 |
2014 |
|
rs2981582
|
|
|
0.020 |
GeneticVariation |
BEFREE |
FGFR2 rs2981582 was confirmed to be significantly associated with the risk of ER-positive but not ER-negative breast cancer.
|
23143756 |
2013 |
|
rs700518
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Genetic polymorphism at Val80 (rs700518) of the CYP19A1 gene is associated with aromatase inhibitor associated bone loss in women with ER + breast cancer.
|
23643682 |
2013 |
|
rs10069690
|
|
|
0.020 |
GeneticVariation |
BEFREE |
We identified a common risk variant for ER-negative breast cancer at the TERT-CLPTM1L locus on chromosome 5p15 (rs10069690: per-allele odds ratio (OR) = 1.18 per allele, P = 1.0 × 10(-10)).
|
22037553 |
2011 |
|
rs2046210
|
|
|
0.020 |
GeneticVariation |
BEFREE |
In contrast, SNP rs2046210 at 6q25.1 near ESR1 was primarily associated with ER-negative breast cancer risk for both BRCA1 and BRCA2 carriers.
|
22053997 |
2011 |
|
rs2981582
|
|
|
0.020 |
GeneticVariation |
BEFREE |
We also confirmed that SNPs in FGFR2 and TNRC9 were associated with greater risk of estrogen receptor-positive than estrogen receptor-negative breast cancer (P(heterogeneity) = .0016 for FGFR2-rs2981582 and P(heterogeneity) = .0053 for TNRC9-rs3803662).
|
21791674 |
2011 |
|
rs6596100
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The two other interactions suggested stronger associations between SNP rs6596100 and ER-negative breast cancer with increasing parity and younger age at first birth.
|
31605532 |
2019 |
|
rs121434592
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Both assays are employed at centralized testing laboratories operating according to quality standards for prospective identification of the AKT1 E17K mutation in ER+ breast cancer patients in the context of a clinical trial evaluating the AKT inhibitor AZD5363 in combination with endocrine (fulvestrant) therapy.
|
28472036 |
2017 |
|
rs13267382
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The remaining two gene-environment interactions were also identified in relation to ER- breast cancer risk and were found between 3p21-rs6796502 and age at menarche (OR<sub>int</sub> = 1.26, 95% CI: 1.12-1.43, p<sub>int</sub> =1.8 × 10<sup>-4</sup> ) and between 8q23-rs13267382 and age at first full-term pregnancy (OR<sub>int</sub> = 0.89, 95% CI: 0.83-0.95, p<sub>int</sub> = 5.2 × 10<sup>-4</sup> ).
|
28670784 |
2017 |
|
rs190843378
|
|
|
0.010 |
GeneticVariation |
BEFREE |
PRKAG3 (Padj = 0.0018) and RPS6KA3 (Padj = 0.061) were the leading genes for the associations with overall breast cancer risk and ER- breast cancer risk, respectively. rs190843378 in PRKAG3 was statistically significant after gene-level adjustment for multiple comparisons (OR = 0.50 for each T allele, 95% CI = 0.38-0.66, Padj = 3.6E-05), with a statistical power of 0.914.
|
28582508 |
2017 |
|
rs4245739
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We demonstrate that the application of these two methods, in particular the miRNA profile approach, permits detection of new molecular and clinical features related to the rs4245739 variant in ER-negative breast cancer.
|
29372105 |
2017 |
|
rs6796502
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The remaining two gene-environment interactions were also identified in relation to ER- breast cancer risk and were found between 3p21-rs6796502 and age at menarche (OR<sub>int</sub> = 1.26, 95% CI: 1.12-1.43, p<sub>int</sub> =1.8 × 10<sup>-4</sup> ) and between 8q23-rs13267382 and age at first full-term pregnancy (OR<sub>int</sub> = 0.89, 95% CI: 0.83-0.95, p<sub>int</sub> = 5.2 × 10<sup>-4</sup> ).
|
28670784 |
2017 |
|
rs10822013
|
|
|
0.010 |
GeneticVariation |
BEFREE |
When stratified based on breast cancer subtype, our analyses revealed that three SNPs (rs981782, rs10759243 and rs704010) correlated with ER+ breast cancer, while another three (rs4973768, rs1432679 and rs10822013) correlated with ER- breast cancer.
|
27863437 |
2016 |
|
rs12998806
|
|
|
0.010 |
GeneticVariation |
BEFREE |
In addition, we confirmed SNP rs10069690 was the best indicator for ER-negative breast cancer at 5p15.33 (OR = 1.30; P = 2.4 × 10 − 10) and identified rs12998806 as the best indicator for ER-positive breast cancer at 2q35 (OR = 1.34; P = 2.2 × 10 − 8) for women of African ancestry.
|
28171663 |
2016 |
|
rs13074711
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We found that SNP rs13074711, 26.5 Kb upstream of TNFSF10 at 3q26.21, was significantly associated with risk of oestrogen receptor (ER)-negative breast cancer (odds ratio [OR]=1.29, 95% CI: 1.18-1.40; P = 1.8 × 10 − 8).
|
28171663 |
2016 |
|
rs1432679
|
|
|
0.010 |
GeneticVariation |
BEFREE |
When stratified based on breast cancer subtype, our analyses revealed that three SNPs (rs981782, rs10759243 and rs704010) correlated with ER+ breast cancer, while another three (rs4973768, rs1432679 and rs10822013) correlated with ER- breast cancer.
|
27863437 |
2016 |
|
rs4973768
|
|
|
0.010 |
GeneticVariation |
BEFREE |
When stratified based on breast cancer subtype, our analyses revealed that three SNPs (rs981782, rs10759243 and rs704010) correlated with ER+ breast cancer, while another three (rs4973768, rs1432679 and rs10822013) correlated with ER- breast cancer.
|
27863437 |
2016 |
|
rs704010
|
|
|
0.010 |
GeneticVariation |
BEFREE |
When stratified based on breast cancer subtype, our analyses revealed that three SNPs (rs981782, rs10759243 and rs704010) correlated with ER+ breast cancer, while another three (rs4973768, rs1432679 and rs10822013) correlated with ER- breast cancer.
|
27863437 |
2016 |
|
rs981782
|
|
|
0.010 |
GeneticVariation |
BEFREE |
When stratified based on breast cancer subtype, our analyses revealed that three SNPs (rs981782, rs10759243 and rs704010) correlated with ER+ breast cancer, while another three (rs4973768, rs1432679 and rs10822013) correlated with ER- breast cancer.
|
27863437 |
2016 |
|
rs2059614
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We identified one new locus (rs2059614 at 11q24.2) associated with survival in ER-negative breast cancer cases (hazard ratio [HR] = 1.95, 95% confidence interval [CI] = 1.55 to 2.47, P = 1.91 x 10(-8)).
|
25890600 |
2015 |
|
rs2016347
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We provide the first evidence for IGF1R_rs2016347 as an independent prognostic marker for ER+ breast cancer patients treated with TAM and support a rational for combined treatment strategies.
|
23459444 |
2014 |
|
rs3020314
|
|
|
0.010 |
GeneticVariation |
BEFREE |
When stratified by ER status, ESR1 rs1801132, rs2046210, and rs3020314 showed stronger associations in ER-positive than in ER-negative breast cancer in only EA women.
|
25228414 |
2014 |
|
rs250108
|
|
|
0.010 |
GeneticVariation |
BEFREE |
In contrast, FGF1 rs250108 was significantly associated with the risk of ER-negative breast cancer (OR (95% CI) = 1.68 (1.20-2.35) for CT + TT vs. CC genotype) but not ER-positive breast cancer.
|
23143756 |
2013 |